Search
Research
Combining CRISPR-Cas9 and TCR exchange to generate a safe and efficient cord blood-derived T cell product for pediatric relapsed AMLHematopoietic cell transplantation (HCT) is an effective treatment for pediatric patients with high-risk, refractory, or relapsed acute myeloid leukemia (AML). However, a large proportion of transplanted patients eventually die due to relapse. To improve overall survival, we propose a combined strategy based on cord blood (CB)-HCT with the application of AML-specific T cell receptor (TCR)-engineered T cell therapy derived from the same CB graft.
Research
Network analysis of immunotherapy-induced regressing tumours identifies novel synergistic drug combinationsCancer immunotherapy has shown impressive results, but most patients do not respond.
Research
Relapse and outcome patterns of patients with central nervous system mixed malignant germ cell tumors treated without irradiationThis study investigated the relapse and outcome patterns of patients with central nervous system mixed malignant germ cell tumors treated with chemotherapy-only
Research
Relapse and outcome patterns of patients with central nervous system mixed malignant germ cell tumors treated without irradiationThis study investigates the different patterns of relapse in patients with central nervous system mixed malignant germ cell tumors - treated with chemotherapy.
Research
The MOBI-Kids Study Protocol: Exposure to Electromagnetic Fields from Wireless Telecommunication Technologies and Possible Association with Brain Tumor RiskThe rapid increase in mobile phone use in young people has generated concern about possible health effects of exposure to radiofrequency (RF) and extremely...